{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:23:51Z","timestamp":1770506631852,"version":"3.49.0"},"reference-count":116,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The number of medications used to treat different types of seizures has increased over the last 10\u201315 years. Most of the newer antiepileptic drugs (AEDs) are likely to be unfamiliar to many nephrologists. For both the older and newer AEDs, basic pharmacokinetic information, recommendations for drug dosing in patients with reduced kidney function or who are on dialysis, and adverse renal and fluid\u2010electrolyte effects are reviewed. Newer AEDs are less likely to have significant drug\u2013drug interactions than older agents, but are more likely to need dosage adjustment in patients with reduced kidney function. The most common renal toxicities of these drugs include metabolic acidosis, hyponatremia, and nephrolithiasis; interstitial nephritis and other adverse effects are less common. Little is known about the clearance of most of the newer AEDs with high\u2010efficiency hemodialyzers or with peritoneal dialysis. Monitoring of drug levels when available, careful clinical assessment of patients taking AEDs, and close collaboration with neurologists is essential to the management of patients taking AEDs.<\/jats:p>","DOI":"10.1111\/j.1525-139x.2006.00195.x","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T15:35:39Z","timestamp":1158075339000},"page":"408-416","source":"Crossref","is-referenced-by-count":44,"title":["Use of Antiepileptic Drugs in Patients with Kidney Disease"],"prefix":"10.1111","volume":"19","author":[{"given":"Rubeen K.","family":"Israni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishaminy","family":"Kasbekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5_Suppl_4.S2"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.3.395"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-33046"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606133342407"},{"key":"e_1_2_5_6_2","volume-title":"Goodman and Gilman's Pharmacological Basis of Therapeutics","author":"Gilman AG","year":"2005"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.99"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.25"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199602000-00016"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199109000-00004"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601183340308"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200202000-00016"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200306000-00016"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.235"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.13001.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.03601.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.04.016"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/clinchem\/45.6.829","article-title":"Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin","volume":"45","author":"Roberts WL","year":"1999","journal-title":"Clin Chem"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/clinchem\/47.5.910","article-title":"Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin","volume":"47","author":"Annesley TM","year":"2001","journal-title":"Clin Chem"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027878"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.238.16.1750"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(85)80220-3"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)80360-6"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1970.00480190049008"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.138.2.299"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1974.tb01550.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-005-1947-0"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000049045"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP57484"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-100100938"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/18.1.220"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563658008989993"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00409-5"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-2977(96)00070-8"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP57310"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02930.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-38-3-356"},{"key":"e_1_2_5_38_2","first-page":"289","article-title":"The antidiuretic action of carbamazepine in man","volume":"47","author":"Meinders AE","year":"1974","journal-title":"Clin Sci Mol Med"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10190"},{"key":"e_1_2_5_40_2","first-page":"419","article-title":"Effect of carbamazepine on plasma and urine arginine\u2010vasopressin","volume":"54","author":"Thomas TH","year":"1978","journal-title":"Clin Sci Mol Med"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-57-5-952"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000169018"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.9.1456"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120025355"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19387"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184867"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(02)00007-4"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.05504.x"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430219"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808702100306"},{"key":"e_1_2_5_51_2","first-page":"263","volume-title":"Handbook of Dialysis","author":"Daugirdas JT","year":"2001"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198301000-00003"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199005000-00012"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16207"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03766.x"},{"key":"e_1_2_5_56_2","first-page":"1030","article-title":"Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child","volume":"11","author":"Marquardt ED","year":"1992","journal-title":"Clin Pharm"},{"issue":"1","key":"e_1_2_5_57_2","first-page":"S24","article-title":"Peritoneal kinetics of different drugs","volume":"30","author":"Keller E","year":"1988","journal-title":"Clin Nephrol"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30965-4"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976202213"},{"key":"e_1_2_5_60_2","first-page":"213","article-title":"The absorption and excretion of ethosuximide","volume":"7","author":"Buchanan RA","year":"1973","journal-title":"Int J Clin Pharmacol"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/0049825021000061606"},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01001-7"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1983.04050120047006"},{"key":"e_1_2_5_64_2","first-page":"1757","article-title":"Hemodialysis clearance of ethosuximide in patients with chronic renal disease","volume":"38","author":"Marbury TC","year":"1981","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050934"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.35.587"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.50.8.658"},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130303"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00313107"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1982.tb02679.x"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198403000-00001"},{"key":"e_1_2_5_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259955"},{"key":"e_1_2_5_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027276"},{"key":"e_1_2_5_74_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563658308990598"},{"key":"e_1_2_5_75_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164101101199414"},{"key":"e_1_2_5_76_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123693.82339.FC"},{"key":"e_1_2_5_77_2","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man","volume":"36","author":"Vollmer KO","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_5_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.118"},{"key":"e_1_2_5_79_2","unstructured":"Gabapentin (Neurontin) package insert. Morris Plains NJ:Parke\u2010Davis 2002"},{"key":"e_1_2_5_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb05020.x"},{"key":"e_1_2_5_81_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ajhp\/52.1.61","article-title":"Gabapentin and lamotrigine: novel antiepileptic drugs","volume":"52","author":"Btaiche IF","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_5_82_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.17.1375.34432"},{"key":"e_1_2_5_83_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.13101.x"},{"key":"e_1_2_5_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00309-6"},{"key":"e_1_2_5_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"key":"e_1_2_5_86_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002"},{"key":"e_1_2_5_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80006-9"},{"key":"e_1_2_5_88_2","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1997.0124"},{"key":"e_1_2_5_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2005.55204.x"},{"key":"e_1_2_5_90_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.41701.x"},{"key":"e_1_2_5_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.6.554"},{"key":"e_1_2_5_92_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.1.105.34662"},{"key":"e_1_2_5_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02459.x"},{"key":"e_1_2_5_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00781.x"},{"issue":"3","key":"e_1_2_5_95_2","first-page":"S153","article-title":"Nephrolithiasis during treatment with topiramate [abstract]","volume":"36","author":"Wasserstein AG","year":"1995","journal-title":"Epilepsia"},{"key":"e_1_2_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.04.009"},{"key":"e_1_2_5_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04406.x"},{"key":"e_1_2_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2004.04.016"},{"key":"e_1_2_5_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.30603.x"},{"key":"e_1_2_5_100_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630060-00001"},{"key":"e_1_2_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.07.004"},{"key":"e_1_2_5_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb05939.x"},{"key":"e_1_2_5_103_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb05938.x"},{"key":"e_1_2_5_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194967"},{"key":"e_1_2_5_105_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700913"},{"key":"e_1_2_5_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb06000.x"},{"key":"e_1_2_5_107_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00619.x"},{"key":"e_1_2_5_108_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.32500.x"},{"key":"e_1_2_5_109_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073897012001041"},{"key":"e_1_2_5_110_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346010-00009"},{"key":"e_1_2_5_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1997.tb00133.x"},{"key":"e_1_2_5_112_2","first-page":"25","article-title":"Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis","volume":"19","author":"Fillastre JP","year":"1993","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_5_113_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100020904"},{"key":"e_1_2_5_114_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.19107"},{"key":"e_1_2_5_115_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855030-00013"},{"key":"e_1_2_5_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00048-8"},{"key":"e_1_2_5_117_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01272.x"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-139X.2006.00195.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-139X.2006.00195.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:25:17Z","timestamp":1697088317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-139X.2006.00195.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1525-139X.2006.00195.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-139x.2006.00195.x","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}